ClinicalTrials.gg
CompletedNCT07213895Updated Oct 9, 2025

Bioequivalence Study to Compare Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended-Release Tablets Versus Trijardy® XR Extended Release Film Coated Tablets

A Phase 1 interventional study of Empagliflozin/Linagliptin/Metformin HCL and Trijardy® XR Extended release film coated tablets in Type 2 Diabetes Mellitus (T2DM), sponsored by Humanis Saglık Anonim Sirketi. Completed at 1 site in Jordan. Open to participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-10-09.

Sponsored by Humanis Saglık Anonim Sirketi · Phase 1, Interventional, and Other

From the registry’s dates

  • Registered 4 months after the study started (first participant enrolled May 2025, registered Oct 2025).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
14
Allocation
Randomized
Ages
18 Years to 50 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 — 18 open to participants now, 19 under way, 1 of them phase 3. empagliflozin · Diabetes Mellitus, Type 2.

Enrollment
121st of 130
14 · median 79
Started
2025
with 10 others
Phase 1
24 of 130
5 open now
Registered
118th of 130
by date
Lead sponsor
8 of 130
Humanis Saglık Anonim Sirketi

Among the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, this one is the 121st largest by enrollment, is one of 11 that started in 2025, is one of 24 in phase 1, and was the 118th registered.

Diabetes Mellitus, Type 2

10,386 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,411 are open to participants now.

Browse Diabetes Mellitus, Type 2 studies →

Open to participants now

18 of the 130 studies testing empagliflozin in Diabetes Mellitus, Type 2 are open now, in 10 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About empagliflozin

empagliflozin: first FDA approval 2014 (JARDIANCE), first EMA approval 2014. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 880 Diabetes Mellitus, Type 2 studies recruiting now, 374 (43%) set no upper age limit and 380 (43%) stop at 75 or younger; 52 take children under 18; 204 take healthy volunteers.

This study: 18 Years to 50 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 130 studies testing empagliflozin in Diabetes Mellitus, Type 2, or all of them as a file.
02

Study summary

Randomized, Single Oral Dose, Two-period, Two Sequence, Open-label, Crossover, Bioequivalence Study to Compare Empagliflozin-Linagliptin-Metformin XR Tablet 25mg/ 5mg/1000mg (25mg Empagliflozin /5mg Linagliptin /1000mgMetformin Hydrochloride) Versus Trijardy® XR Tablets (25mg Empagliflozin /5mg Linagliptin /1000mg Metformin Hydrochloride), in Healthy Subjects Under Fed Conditions.

03

Conditions studied

  • Type 2 Diabetes Mellitus (T2DM)
04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The subject is caucasian \& aged between eighteen \& fifty years (18-50), both inclusive.
  • The subject is within the limits for his/her height \& weight as defined by the range (18.5 - 30.0 kg/m2).
  • The subject is willing to undergo the necessary pre- \& post- medical examinations set by this study.
  • The results of medical history, physical examination, vital signs \& conducted medical laboratory tests are normal as determined by the clinical investigator.
  • The subject tested negative for (HBsAg), (HCVAb) and (HIVAb).
  • There is no evidence of psychiatric disorder, antagonistic personality, and poor motivation, emotional or intellectual problems likely to limit the validity of consent to participate in the study or limit the ability to comply with protocol requirements.
  • The subject is able to understand and willing to sign the form.
  • For female subjects: negative serum pregnancy test and the woman is using two reliable methods and should be non-lactating.
  • The subject has normal cardiovascular system \& normal with normal corrected for heart rate according to Bazett's formula.
  • The subject's kidney and liver ( \& ALT enzymes) function tests are within normal range. (Creatinine is accepted if below the reference range after being evaluated by the clinical investigator as clinically not significant).
  • The subject's test result is within normal range (HbA1c is accepted if below the reference range after being evaluated by the clinical investigator as clinically not significant.)
  • The subject's fasting blood glucose level is ≥ 70 mg/dL before dosing.
  • The subject Hematology test results are within normal range \& RBC indices are within 5% of the normal range.

Exclusion criteria

Exclusion Criteria:

  • The subject is a heavy smoker (more than 10 cigarettes per day).
  • The subject has suffered an acute illness one week before dosing.
  • The subject has a history of or concurrent abuse of alcohol.
  • The subject has a history of or concurrent abuse of illicit drugs.
  • The subject has a history of and/or to the study drug and any related compounds.
  • The subject has been hospitalized within three months before the study or during the study.
  • The subject is on special diet (for example subject is vegetarian).
  • The subject has consumed caffeine or xanthine containing beverages or foodstuffs within two days before dosing and until 72 hours after dosing in both study periods.
  • The subject has taken a prescription medication within two weeks or even an over the counter product (OTC) within one week before dosing in each study period and any time during the study, unless otherwise judged acceptable by the clinical investigator.
  • The subject has taken grapefruit/ orange containing beverages or foodstuffs within seven (7) days before first dosing and any time during the study.
  • The subject has been participating in any clinical study (e.g. pharmacokinetics, bioavailability and bioequivalence studies) within the last 80 days prior to the present study.
  • The subject has donated blood within 80 days before first dosing.
  • The subject has a history or presence of cardiovascular, pulmonary, renal, hepatic, gastrointestinal, hematological, endocrinal, immunological, dermatological, neurological, musculoskeletal or psychiatric diseases.
  • The subject has consumed drugs that may affect pharmacological/ pharmacokinetic properties of Empagliflozin/Linagliptin/Metformin hydrochloride (for example: Ethanol, Ioversol, Probenecid, Iodinated contrast media, Rifampicin, Gemfibrozil, Glimepiride, Sitagliptin, Warfarin, Verapamil, Ramipril, Torasemide, Hydrochlorothiazide, Lithium, Cimetidine, apalutamide, Benazepril, Idelalisib, Ivosidenib, Lasmiditan, Methylene blue, Ranolazine, Selegiline, Tafenoquine, Tedizolid, Tranylcypromine, Tucatinib, Voxelotor, Sulphonylureas, Ritonavir, Dolutegravir, Cimetidine, Trimethoprime, Isavuconazonium, Crizotinib, Olaparib, Trimethoprime, Vandetanib, Isavuconazole, , Insulin and insulin secretagogues (Sulphonylureas)) two weeks before and after the study and during the study.
  • The subject has a history of ketone in urine, presence of any type of acute metabolic acidosis (such as lactic acidosis).

Note: Subjects, who were screened for another study and were not enrolled, might be recruited for this study provided they meet the acceptance criteria of the study.

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Randomized
Intervention model
Crossover assignment
Masking
None (open label)
Enrollment
14 participants (actual)

Study arms

  • Experimental
    Empagliflozin/Linagliptin/Metformin HCL Extended Release Tablets

    Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg Extended Release Tablets

    Drug: Empagliflozin/Linagliptin/Metformin HCL · Drug: Trijardy® XR Extended release film coated tablets

  • Active comparator
    Trijardy® XR Extended release film coated tablets

    Trijardy® 25mg/5mg/1000mg Extended release film coated tablets

    Drug: Empagliflozin/Linagliptin/Metformin HCL · Drug: Trijardy® XR Extended release film coated tablets

Interventions

  • DrugEmpagliflozin/Linagliptin/Metformin HCL

    Drug pages: Empagliflozin · Linagliptin · Metformin

    One Empagliflozin/Linagliptin/Metformin HCL 25mg/5mg/1000mg extended release film-coated tablet

  • DrugTrijardy® XR Extended release film coated tablets

    One Trijardy® 25mg/5mg/1000mg Extended Release Tablets

06

What researchers measure

Primary outcomes

  1. For Empagliflozin & Linagliptin & Metformin; Maximum concentration obtained (Cmax)

    two-sides 90% CI for the test to reference ratio of the population means is within 80.00-125.00% for each of the Ln-transformed data Cmax

    Time frame: 72 hours

  2. For Linagliptin; AUC from time 0 to last collection time (AUC0 - 72 due to Linagliptin long half-life)

    two-sides 90% CI for the test to reference ratio of the population means is within 80.00-125.00% for each of the Ln-transformed data AUC

    Time frame: 72 hours

  3. For Metformin; AUC from time 0 to last collection time (AUC0-t)

    two-sides 90% CI for the test to reference ratio of the population means is within 80.00-125.00% for each of the Ln-transformed data AUC

    Time frame: 72 hours

Secondary outcomes

  1. For Empagliflozin & Linagliptin & Metformin; Time to reach maximum concentration Cmax (Tmax)

    Descriptive Statistics

    Time frame: 72 hours

07

Study locations

1 site
  • ACDIMA Center
    Amman, 925161, Jordan
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from May 2025 to primary completion in Sep 2025, 3 months.

Of 453 industry-sponsored phase 1 interventional studies under Diabetes Mellitus, Type 2, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 11. This study's 3 months is below that.

Counting every sponsor, half of 515 studies reached it within 6 months; a quarter within 2 and three quarters within 14.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 2, 2025
First posted
Oct 9, 2025
StartActual
May 21, 2025
Primary completionActual
Sep 15, 2025
CompletionActual
Sep 18, 2025
Last update
Oct 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07213895
Responsible party
Sponsor
First posted
Oct 9, 2025
Start date
May 21, 2025
Primary completion
Sep 15, 2025
Completion
Sep 18, 2025
Last update
Oct 9, 2025

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Empagliflozin · Linagliptin · Metformin

Start the discussion